Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: TIKOSYN

« Back to Dashboard

Tikosyn is a drug marketed by Pfizer and is included in one NDA. It is available from one supplier. There is one patent protecting this drug and one Paragraph IV challenge.

The generic ingredient in TIKOSYN is dofetilide. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the dofetilide profile page.

Summary for Tradename: TIKOSYN

Patents:1
Applicants:1
NDAs:1
Suppliers: see list1

Pharmacology for Tradename: TIKOSYN

Drug ClassAntiarrhythmic

Clinical Trials for: TIKOSYN

Ability of Late Sodium or Calcium Current Block to Balance the ECG Effects of Potassium Current Block
Status: Completed Condition: Drug-induced QT Prolongation; Pharmacokinetics; Pharmacodynamics

PVI Using Cryoablation Alone in Paroxysmal AF Patients Converted From Persistent AF With Dofetilide
Status: Not yet recruiting Condition: Paroxysmal Atrial Fibrillation; Persistent Atrial Fibrillation

Study of the Electrocardiographic Effects of Ranolazine, Dofetilide, Verapamil, and Quinidine in Healthy Subjects
Status: Active, not recruiting Condition: Drug-induced Surface ECG Changes

Using an iPhone ECG to Monitor the QT Interval on Dofetilide and Sotalol Patients
Status: Recruiting Condition: Cardiac Arrhythmia; Qt Interval, Variation in

High Intensity Focused Ultrasound (HIFU) Ablation System Study
Status: Suspended Condition: Atrial Fibrillation

AV Node Ablation and Pacemaker Therapy Compared to Drug Therapy for Atrial Fibrillation - Pilot Study
Status: Terminated Condition: Atrial Fibrillation; Heart Failure

Catheter Ablation for Recently Diagnosed Paroxysmal Atrial Fibrillation
Status: Withdrawn Condition: Atrial Fibrillation

A Study of the Effectiveness of Anti-Arrhythmic Medications After Atrial Fibrillation Ablation
Status: Completed Condition: Atrial Fibrillation

A Comparison of Antiarrhythmic Drug Therapy and Radio Frequency Catheter Ablation in Patients With Paroxysmal Atrial Fibrillation
Status: Completed Condition: Paroxysmal Atrial Fibrillation

Catheter Ablation Versus Amiodarone for Shock Prophylaxis in Defibrillator Patients With Ventricular Tachycardia
Status: Terminated Condition: Defibrillators, Implantable; Tachycardia, Ventricular

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer
TIKOSYN
dofetilide
CAPSULE;ORAL020931Oct 1, 1999RXNo6,124,363<disabled><disabled>
Pfizer
TIKOSYN
dofetilide
CAPSULE;ORAL020931Oct 1, 1999RXYes6,124,363<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: TIKOSYN

Drugname Dosage Strength RLD Submissiondate
dofetilideCapsules0.125 mg, 0.25 mg, and 0.5 mgTikosyn5/1/2014
« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology

`abc